Five Prime Therapeutics (FPRX) to Release Quarterly Earnings on Tuesday

Five Prime Therapeutics (NASDAQ:FPRX) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 6th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.99) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.30. The company had revenue of $7.58 million for the quarter, compared to the consensus estimate of $5.87 million. Five Prime Therapeutics had a negative return on equity of 40.61% and a negative net margin of 206.02%. On average, analysts expect Five Prime Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

NASDAQ FPRX opened at $12.83 on Friday. Five Prime Therapeutics has a fifty-two week low of $11.72 and a fifty-two week high of $45.97.

Several equities analysts recently weighed in on FPRX shares. Citigroup lowered their target price on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 20th. Wells Fargo & Co lowered their target price on Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a research report on Thursday, August 9th. BidaskClub downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Wedbush lifted their target price on Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a research report on Friday, August 10th. Finally, ValuEngine downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. Five Prime Therapeutics has a consensus rating of “Hold” and a consensus price target of $31.70.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

See Also: Fundamental Analysis

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply